Affiliation:
1. Ateos Foundation of Science Education and Research, Pune, Maharashtra, India
Abstract
Growth factors receptors and hormones play an important role several cell minor cell types.With advent of advancement in Breast cancer (BC) treatment and therapies ther of there has been major advancement in this area after this discovery. The combined sciences of cellular biology and therapeutic fields have made the breast cancer a seized cure area for discoveries of new therapies and its design including the heterogeneity. This article reviews the numerous prospective innovative therapies for targeting major cell subtypes of BC cells, as well as the present therapeutic regimens. In the personalised BC drug, speedy scientific advancement of poly inhibitors (ADP-ribose) polymerase, cyclin-dependent kinases four and six, phosphatidylinositol 3-kinase / protein kinase b / mammalian target rapamycin pathway, histone deacetylation, multi-concentrated in tyrosine kinases, as well as antibodies. The Triple negative breast cancer (TNBC) has been the most challenging area for design of therapies and for drug discovery. For TNBC, as such there is no approved treatment and it is most dangerous type of BC. The article also discusses the TNBC heterogeneity and TNBC molecular subtyping. It could also help find medications to treat this terrible disease. The cell proliferation and propagation inhibitors for treatment-resistant strains also puts the invention of targets for small molecules of BC in concern.
Publisher
IP Innovative Publication Pvt Ltd
Reference28 articles.
1. Hosseini M, Hassannejad R, Khademolghorani S H, Tabatabaeian M, Mokarian F, Identification of Patterns of Breast Cancer Metastasis among Women Referred to Isfahan Seyedoshohada Center, Iran, between 1999 and 2009 by Association Rules and Ordinal Logistic Regression.Sci Res J Health Syst Res 2012;7(6):746-62
2. Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays
3. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome
4. Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831
5. Peto R, Davies C, Godwin J, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.Lancet 2012;379(9814):61625-30